Physician profile
Thomas Hart
NPI 1417474180
$2,109.78
in general payments reported to CMS, 2019-2025
22 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $123 · 2023: $101 · 2024: $21.85 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641 · Travel and Lodging: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.83 |
| Travel and Lodging | $639.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $972.98 | 2025 | General - Therapies, Overstitch Endoscopic Suturing System |
| Abbvie INC. | $140.96 | 2021-2023 | |
| Novo Nordisk INC | $127.47 | 2023-2025 | Wegovy |
| Lilly USA, LLC | $122.29 | 2021-2022 | |
| Ucb, INC. | $110.86 | 2021 | |
| Intuitive Surgical, INC. | $108.52 | 2025 | |
| Sunovion Pharmaceuticals INC. | $89.60 | 2021 | |
| Reshape Lifesciences INC. | $63.51 | 2021-2023 | |
| Amneal Pharmaceuticals LLC | $46.12 | 2021 | |
| Avanir Pharmaceuticals, INC. | $43.84 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $39.30 | 2021 | |
| W. L. Gore & Associates, INC. | $35.40 | 2023-2024 | Gore Seamguard Bioabsorbable Staple Line Reinforce, Gore Synecor Biomaterial |
| Almatica Pharma LLC | $30.62 | 2021 | |
| Emd Serono, INC. | $30.17 | 2021 | |
| Sk Life Science, INC. | $26.99 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $22.10 | 2021 | |
| Eisai INC. | $20.14 | 2021 | |
| Adamas Pharmaceuticals, INC. | $19.71 | 2021 | |
| Kyowa Kirin, INC. | $16.85 | 2021 | |
| Neurelis, INC. | $16.01 | 2021 | |
| Neurocrine Biosciences, INC. | $14.88 | 2021 | |
| Tanabe Pharma America, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.